Literature DB >> 19806318

Procalcitonin as an early marker of bacterial infection in neutropenic febrile children with acute lymphoblastic leukemia.

Maria Hatzistilianou1, Aleka Rekliti, Fanni Athanassiadou, Dorothea Catriu.   

Abstract

OBJECTIVE AND
DESIGN: The aim of this study was to assess the value of procalcitonin (PCT), C-reactive protein (CRP), tumor necrosis factor-alpha (TNF-a), interleukin (IL)-1b, IL-8, and soluble TNF receptor II (sTNFRII) in early and rapid diagnosis of infection in neutropenic children with acute lymphoblastic leukemia (ALL) and to distinguish bacterial from viral infections. PATIENTS: The study included five groups (A, B, C, D, and E) of children with ALL undergoing intensive chemotherapy. Groups A and B consisted of neutropenic children with bacterial and viral infection, respectively. Groups C and D consisted of nonneutropenic children with bacterial and viral infection, respectively. Group E consisted of children without neutropenia and without fever.
METHODS: In all groups, blood samples were collected upon admission and then for 7 days on a daily basis. Levels of CRP, PCT, TNF-a, IL-1b, IL-8, and sTNFRII were determined in all blood samples.
RESULTS: We found a highly significant difference in PCT levels between bacterial and nonbacterial episodes. Sensitivity and specificity of PCT were 94 and 96.5%, respectively.
CONCLUSIONS: Serial measurement of PCT levels on a daily basis seems to be helpful for early prediction of severe bacterial infections, monitoring febrile episodes regarding response to antibiotic therapy, and early detection of complications in the infectious process.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19806318     DOI: 10.1007/s00011-009-0100-0

Source DB:  PubMed          Journal:  Inflamm Res        ISSN: 1023-3830            Impact factor:   4.575


  29 in total

1.  Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial.

Authors:  Mirjam Christ-Crain; Daiana Jaccard-Stolz; Roland Bingisser; Mikael M Gencay; Peter R Huber; Michael Tamm; Beat Müller
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

Review 2.  1997 guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. Infectious Diseases Society of America.

Authors:  W T Hughes; D Armstrong; G P Bodey; A E Brown; J E Edwards; R Feld; P Pizzo; K V Rolston; J L Shenep; L S Young
Journal:  Clin Infect Dis       Date:  1997-09       Impact factor: 9.079

3.  Procalcitonin as an early marker of bacterial infection in severely neutropenic febrile adults.

Authors:  L Bernard; F Ferrière; P Casassus; F Malas; S Lévêque; L Guillevin; O Lortholary
Journal:  Clin Infect Dis       Date:  1998-10       Impact factor: 9.079

4.  Regulated production of type I collagen and inflammatory cytokines by peripheral blood fibrocytes.

Authors:  J Chesney; C Metz; A B Stavitsky; M Bacher; R Bucala
Journal:  J Immunol       Date:  1998-01-01       Impact factor: 5.422

Review 5.  From the Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient. Report of a consensus panel.

Authors: 
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

6.  Serum adenosine deaminase and procalcitonin concentrations in neutropenic febrile children with acute lymphoblastic leukaemia.

Authors:  S Hitoglou-Hatzi; M Hatzistilianou; D Gougoustamou; A Rekliti; Ch Agguridaki; F Athanassiadou; S Frydas; A Kotsis; D Catriu
Journal:  Clin Exp Med       Date:  2005-07       Impact factor: 3.984

Review 7.  Febrile neutropenia in children.

Authors:  F Crokaert
Journal:  Int J Antimicrob Agents       Date:  2000-10       Impact factor: 5.283

8.  Diagnostic value of procalcitonin, interleukin-6, and interleukin-8 in critically ill patients admitted with suspected sepsis.

Authors:  S Harbarth; K Holeckova; C Froidevaux; D Pittet; B Ricou; G E Grau; L Vadas; J Pugin
Journal:  Am J Respir Crit Care Med       Date:  2001-08-01       Impact factor: 21.405

9.  The diagnostic value of C-reactive protein, interleukin-8, and monocyte chemotactic protein in risk stratification of febrile neutropenic children with hematologic malignancies.

Authors:  Shereen Mohamed El-Maghraby; Manar Mohamed Moneer; Manar Mohamed Ismail; Lobna M Shalaby; Hadir Ahmed El-Mahallawy
Journal:  J Pediatr Hematol Oncol       Date:  2007-03       Impact factor: 1.289

Review 10.  Current approaches for risk stratification of infectious complications in pediatric oncology.

Authors:  Christoph Härtel; Maresa Deuster; Thomas Lehrnbecher; Christian Schultz
Journal:  Pediatr Blood Cancer       Date:  2007-11       Impact factor: 3.167

View more
  13 in total

Review 1.  Immune regulation of procalcitonin: a biomarker and mediator of infection.

Authors:  G N Matwiyoff; J D Prahl; R J Miller; J J Carmichael; D E Amundson; G Seda; M Daheshia
Journal:  Inflamm Res       Date:  2012-02-22       Impact factor: 4.575

2.  Value of lipopolysaccharide binding protein as diagnostic marker of infection in adult cancer patients with febrile neutropenia: comparison with C-reactive protein, procalcitonin, and interleukin 6.

Authors:  Luis García de Guadiana-Romualdo; Ignacio Español-Morales; Pablo Cerezuela-Fuentes; Luciano Consuegra-Sánchez; Ana Hernando-Holgado; Patricia Esteban-Torrella; Enrique Jiménez-Santos; Monserrat Viqueira-González; África de Béjar-Almira; María Dolores Albaladejo-Otón
Journal:  Support Care Cancer       Date:  2015-01-07       Impact factor: 3.603

3.  Diagnostic accuracy of lipopolysaccharide-binding protein for predicting bacteremia/clinical sepsis in children with febrile neutropenia: comparison with interleukin-6, procalcitonin, and C-reactive protein.

Authors:  Lidija Kitanovski; Janez Jazbec; Sergej Hojker; Metka Derganc
Journal:  Support Care Cancer       Date:  2013-09-21       Impact factor: 3.603

Review 4.  Biomarkers for pediatric sepsis and septic shock.

Authors:  Stephen W Standage; Hector R Wong
Journal:  Expert Rev Anti Infect Ther       Date:  2011-01       Impact factor: 5.091

5.  Procalcitonin levels predict acute kidney injury and prognosis in acute pancreatitis: a prospective study.

Authors:  Hua-Lan Huang; Xin Nie; Bei Cai; Jiang-Tao Tang; Yong He; Qiang Miao; Hao-Lan Song; Tong-Xing Luo; Bao-Xiu Gao; Lan-Lan Wang; Gui-Xing Li
Journal:  PLoS One       Date:  2013-12-13       Impact factor: 3.240

Review 6.  Use of biomarkers in pediatric sepsis: literature review.

Authors:  Vanessa Soares Lanziotti; Pedro Póvoa; Márcio Soares; José Roberto Lapa E Silva; Arnaldo Prata Barbosa; Jorge Ibrain Figueira Salluh
Journal:  Rev Bras Ter Intensiva       Date:  2016 Oct-Dec

7.  Clinical usefulness of serum procalcitonin level in distinguishing between Kawasaki disease and other infections in febrile children.

Authors:  Na Hyun Lee; Hee Joung Choi; Yeo Hyang Kim
Journal:  Korean J Pediatr       Date:  2017-04-25

8.  Sensitivity and specificity of procalcitonin to determine etiology of diarrhea in children younger than 5 years.

Authors:  Vlora Ismaili-Jaha; Mujë Shala; Mehmedali Azemi; Shqipe Spahiu; Teuta Hoxha; Muharrem Avdiu; Lidvana Spahiu
Journal:  Mater Sociomed       Date:  2014-04-11

Review 9.  Diagnosis and empirical treatment of fever of unknown origin (FUO) in adult neutropenic patients: guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO).

Authors:  W J Heinz; D Buchheidt; M Christopeit; M von Lilienfeld-Toal; O A Cornely; H Einsele; M Karthaus; H Link; R Mahlberg; S Neumann; H Ostermann; O Penack; M Ruhnke; M Sandherr; X Schiel; J J Vehreschild; F Weissinger; G Maschmeyer
Journal:  Ann Hematol       Date:  2017-08-30       Impact factor: 3.673

10.  Predictive value of PCT and IL-6 for bacterial infection in children with cancer and febrile neutropenia.

Authors:  Hilde T van der Galiën; Erik A H Loeffen; Karin G E Miedema; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2018-05-19       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.